ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

R&D leaders at Merck and Sanofi move on

by Megha Satyanarayana
October 9, 2020 | APPEARED IN VOLUME 98, ISSUE 39

 

09839-buscon16-perlmutter.jpg
Credit: Merck & Co.
Roger Perlmutter

After 7 years leading Merck Research Laboratories, Roger Perlmutter will retire at the end of 2020. Under his leadership, Merck has achieved some 100 regulatory approvals for treatments, including medicines for cancer and diabetes. Perlmutter will be succeeded by Dean Li, currently head of discovery sciences and translational medicine. And after 8 years at Sanofi, Chief Scientific Officer Gary Nabel is leaving. His replacement is Frank Nestle, who was named head of Sanofi’s immunology and inflammation programs this summer.

09839-buscon16-nabel.jpg
Credit: Sanofi
Gary Nabel
X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment